供体移植前全骨髓和淋巴细胞照射和环磷酰胺治疗急性髓系白血病
异基因造血干细胞移植 (HCT) 前全骨髓/淋巴细胞照射 (TMLI) 调理的初步研究,随后进行移植后基于环磷酰胺的移植物抗宿主病预防完全缓解的急性髓性白血病
This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia. Total marrow and lymphoid irradiation targets cancer in bone marrow and blood, instead of applying radiation to the whole body. Giving total bone marrow and lymphoid irradiation before a donor transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving total bone marrow and lymphoid irradiation before donor transplant and cyclophosphamide after transplant may work better at treating acute myeloid leukemia.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVE:
I. To evaluate the safety/feasibility of combining a total marrow and lymphoid irradiation (TMLI) transplant conditioning regimen with a post-transplant high dose cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis strategy, through the assessment of: adverse events: type, frequency, severity, attribution, time course, duration and complications: including acute GvHD, infection and delayed neutrophil/platelet engraftment.
SECONDARY OBJECTIVES:
I. To estimate the cumulative incidence (CI) of acute GvHD at 100 days post allogeneic hematopoietic cell transplantation (alloHCT).
II. To estimate the CI of chronic GvHD at 6 months, 1- and 2-years post alloHCT.
III. To estimate GVHD-free relapse-free survival (GRFS) at 1- and 2-years post alloHCT.
IV. To describe the kinetics of immune reconstitution and T cell repertoire in the first year post alloHCT.
V. To estimate overall survival (OS), relapse-free survival (RFS) and CI of relapse, and non-relapse mortality (NRM) at 100 days, 1- and 2-years post alloHCT.
VI. To characterize quality of life using 36-Item Short Form Health Survey (SF-36), Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and M. D. Anderson Symptom Inventory (MDASI) or Pediatric Quality of Life Inventory (PedsQL) at 100 days, 6 months, 1- and 2-years post alloHCT.
VII. To assess bone marrow cellularity from bone marrow samples. VIII. To assess the clonogenic potential of cells from bone marrow samples. IX. To assess stromal damage from bone marrow samples. X. To evaluate cytokines and oxidative stress markers.
OUTLINE: This is a dose-escalation study of TMLI.
Patients undergo TMLI twice daily (BID) on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide intravenously (IV) over 2 hours on days 3 and 4, tacrolimus given by continuous intravenous infusion (CIV) on days 5-90, and filgrastim beginning on day 5 until absolute neutrophil count (ANC) is at least 1,500/mm^3 for 3 consecutive days.
After completion of study treatment, patients are followed for up to 24 months.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Duarte、California、美国、91010
- City of Hope Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- This study is open to patients with acute myeloid leukemia (AML) evaluated within 30 days of the start of conditioning regimen and in first or second complete remission (CR)
- Karnofsky performance status (KPS) >= 70%
- The effects of radiation on the developing fetus are known to be teratogenic; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
- Patients with acute myelogenous leukemia (AML) who are in first or second complete remission
- All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 allele matched unrelated donor; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques; (red cell exchange or plasma exchange)
- A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
- Patients must have a serum creatinine of less than or equal to 1.3 mg/dL or creatinine clearance > 70 ml/min as calculated by the Cockcroft-Gault formula
- A bilirubin of less than or equal to 1.5 mg/dL, excluding patients with Gilbert's disease
- Patients should also have a serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than 5 times the upper limit of normal
- Pulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV 1) and DLCO should be greater than 50% of predicted normal value
- All subjects must have the ability to understand and the willingness to sign a written informed consent; signed informed consent form approved by the Institutional Review Board (IRB) is required; the patient, family member, and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting, all pertinent information with respect to risks and benefits to the donor and recipient will be presented; alternative treatment modalities will be discussed
- The time from the end of last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days
- Prior therapy with etoposide and cyclophosphamide is allowed
- DONOR: donor evaluation and eligibility will be assessed as per current City of Hope standard operating procedure (SOP)
Exclusion Criteria:
- Patients should not have any uncontrolled illness including ongoing or active or poorly controlled infection
- Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; maintenance therapy with Food and Drug Administration (FDA)-approved targeted therapies (e.g. tyrosine kinase inhibitors for Philadelphia chromosome [Ph] positive [+] acute lymphoblastic leukemia [ALL], and FLT inhibitors for FLT3+ patients) will be allowed after day 60 disease assessment
- Prior radiation therapy that would exclude the use of TMLI
- Relapsed patients who have undergone autologous or allogeneic hematopoietic stem cell transplantation previously
- Patients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation
- Electrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction < 50%
- Patients who have been treated with chemotherapy or radiation for the purpose of induction, re-induction or consolidation, within two weeks of planned study enrollment
- Patients with other active malignancies are ineligible for this study, other than localized malignancies
- Patients that are pregnant or breastfeeding
- Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to, infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.
- Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment (TMLI, cyclophosphamide)
Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days. |
Correlative studies Ancillary studies
其他名称:
Given IV
其他名称:
Ancillary studies Undergo alloHCT
其他名称:
Administer according to City of Hope standard operating procedures
其他名称:
Given CIV
其他名称:
Undergo TMLI |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
1a. Incidence of adverse events
大体时间:Up to 24 months
|
Assessed using Bearman Scale Regimen-Related Toxicity scale. Scale range: Grade 0-4 (increasing grade reflects increasing severity), where Grade 0-none/did not experience and Grade 4=death. |
Up to 24 months
|
|
1b. Incidence of adverse events
大体时间:Up to 24 months
|
Assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 scale. Scale range: Grade 1-5 (increasing grade reflects increasing severity), where Grade 1 reflects a more milder form of the adverse event and Grade 5=death. |
Up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
中性粒细胞和血小板恢复/植入的时间
大体时间:从第 0 天到恢复或宣布植入失败,评估长达 24 个月
|
从第 0 天到恢复或宣布植入失败,评估长达 24 个月
|
|
|
骨髓残余损伤评估
大体时间:长达 24 个月
|
长达 24 个月
|
|
|
细胞因子
大体时间:长达 24 个月
|
长达 24 个月
|
|
|
氧化应激标志物
大体时间:长达 24 个月
|
长达 24 个月
|
|
|
Acute graft versus host disease (GvHD)
大体时间:Day 0 to 100 (120) days post-transplant
|
Graded according to the Consensus Grading. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves for that GvHD grade; relapse/death prior to onset will be considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999). |
Day 0 to 100 (120) days post-transplant
|
|
Chronic GVHD
大体时间:From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months
|
The first day of chronic GvHD onset will be used to calculate cumulative incidence curves, with relapse/death prior to onset considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999). |
From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months
|
|
GvHD-free/relapse-free survival (GRFS)
大体时间:From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months
|
Will be calculated using the Kaplan-Meier method. |
From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months
|
|
Levels of immune cells
大体时间:Up to 24 months
|
Will be measured by flow cytometry for cell subsets: a. T-cells. |
Up to 24 months
|
|
Levels of immune cells
大体时间:Up to 24 months
|
Will be measured by flow cytometry for cell subsets: b. B-cells. |
Up to 24 months
|
|
Levels of immune cells
大体时间:Up to 24 months
|
Will be measured by flow cytometry for cell subsets: c. natural killer (NK) cells. |
Up to 24 months
|
|
Levels of immune cells
大体时间:Up to 24 months
|
Will be measured by flow cytometry for cell subsets: d. regulatory T cells (T-regs). |
Up to 24 months
|
|
Overall survival
大体时间:From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months
|
Will be calculated using the Kaplan-Meier method. |
From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months
|
|
Relapse-free survival
大体时间:From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months
|
Will be calculated using the Kaplan-Meier method. |
From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months
|
|
Relapse
大体时间:From start of therapy, assessed up to 24 months
|
Will be calculated using the competing risk method as described by Gooley et al. (1999). |
From start of therapy, assessed up to 24 months
|
|
Non-relapse mortality (NRM)
大体时间:From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months
|
The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. Will be calculated using the Kaplan-Meier method and the competing risk method as described by Gooley et al. (1999). |
From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months
|
|
Quality of life -Questionnaire
大体时间:Up to 24 months
|
Assessed using a. 36-Item Short Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The eight sections are:
|
Up to 24 months
|
|
Quality of life-Function Assessment
大体时间:Up to 24 months
|
Assessed using b. Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). (FACT-BMT) is a 47-item, valid and reliable measure of five dimensions of quality of life in bone marrow transplant patients. The dimensions collected and assessed are:
|
Up to 24 months
|
|
Quality of life -Symptom Inventory
大体时间:Up to 24 months
|
Assessed using c. M. D. Anderson Symptom Inventory (MDASI). MDASI is a multi-symptom patient-reported outcome (PRO) measure for clinical and research use. Use the MDASI to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms. The following parameters will be reported:
|
Up to 24 months
|
合作者和调查者
调查人员
- 首席研究员:Anthony S Stein、City of Hope Medical Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 17423
- 17423 (其他标识符:City of Hope Comprehensive Cancer Center)
- NCI-2018-00177 (注册表标识符:CTRP (Clinical Trial Reporting Program))
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.